Patents Examined by Emily Cordas
-
Patent number: 11753621Abstract: The invention discloses a method for constructing functional exosomes capable of efficiently loading specific miRNA. In order to enable the exosome to carry miRNA with specific regulation function more efficiently so as to play a role in targeted regulation more accurately and efficiently, MS2 phage capsid protein is utilized to edit and construct a capture element of a specific miRNA molecule, and placenta mesenchymal stem cells are reprogrammed to enable the secreted exosome to efficiently load a target miRNA molecule, so that the target miRNA molecule is delivered to tissue cells to play a role in effective regulation, and therefore a new strategy is provided for realizing specific precise treatment in the future.Type: GrantFiled: November 8, 2021Date of Patent: September 12, 2023Assignee: CHINESE PLA GENERAL HOSPITALInventors: Qiankun Li, Wenzhi Hu, Cuiping Zhang, Xiaobing Fu
-
Patent number: 11753623Abstract: Disclosed herein are compositions and methods for treating, ameliorating or preventing a retinal disease or condition; improving a photopic (day light) vision; for improving correcting visual acuity, improving macular function, improving a visual field, or improving scotopic (night) vision by administration of retinal progenitor cells.Type: GrantFiled: June 5, 2018Date of Patent: September 12, 2023Assignee: The Regents of the University of CaliforniaInventors: Henry Klassen, Jing Yang
-
Patent number: 11744856Abstract: Pharmaceutical and cosmetic compositions and methods are presented that have a carrier in combination with a media composition that is derived from distinct cell cultures. The distinct cell cultures are obtained from growing different cells that are distinct with respect to at least one of cell type, cell age, cell differentiation stage, and physiological condition. Thus, the composite medium will provide mediator molecules that are ordinarily not founds in their combination and that can be fine tuned to specific purposes.Type: GrantFiled: September 11, 2017Date of Patent: September 5, 2023Assignee: MediCell Technologies, LLCInventors: Nikolay Turovets, Christopher B. Adams
-
Patent number: 11739293Abstract: The present disclosure relates generally to methods and compositions useful in cell and tissue biology and therapeutics. In particular, an in vitro method for differentiating pluripotent stem cells into KDR+NCAM+APLNR+ mesoderm cells and/or SSEA5?KDR+NCAM+APLNR+ mesoderm cells is provided. The disclosed mesoderm cells may be used to generate blood vessels in vivo and/or further differentiated in vitro into endothelial colony forming cell-like cells (ECFC-like cells). Purified human cell populations of KDR+NCAM+APLNR+ mesoderm cells and ECFC-like cells are provided. Test agent screening and therapeutic methods for using the cell populations of the present disclosure are provided.Type: GrantFiled: August 4, 2017Date of Patent: August 29, 2023Assignee: Indiana University Research and Technology CorporationInventors: Mervin C. Yoder, Nutan Prasain
-
Patent number: 11732285Abstract: Selective enrichment media and methods for selectively growing and detecting Salmonella spp. and/or Shiga toxin-producing E. coli. The media may comprise a carbon and nitrogen source, an inorganic salt, a fermentable sugar, one or more selective agents, and an efflux pump inhibitor. Various selective agents include sulfa drugs, surfactants, aminocoumarins, cycloheximide, supravital stains, ascorbic acid, bromobenzoic acid, myricetin, nitrofurantoin, rifamycins, polyketides, and oxazolidinones. Various efflux pump inhibitors include arylpiperazines, such as 1-(1-naphthylmethyl)piperazine, and quinoline derivatives, such as 4-chloroquinoline. Methods of selectively growing and detecting Salmonella and/or Shiga toxin-producing E. coli are provided.Type: GrantFiled: March 10, 2020Date of Patent: August 22, 2023Assignee: Paradigm Diagnostics, Inc.Inventor: Alan D Olstein
-
Patent number: 11718829Abstract: Embodiments herein include methods, kits, and compositions for manufacturing extracellular matrix (ECM). In some embodiments, the methods comprise differentiating fibroblasts into induced pluripotent stem cells, expanding the induced pluripotent stem cells, and differentiating the induced pluripotent stem cells into fibroblasts. The fibroblasts can produced mature ECM, which can be isolated and used for medical and/or cosmetic products and procedures.Type: GrantFiled: July 28, 2017Date of Patent: August 8, 2023Assignee: Breakthrough Tech LLCInventor: Francis Christopher Zeigler
-
Patent number: 11714031Abstract: A method for visualizing neurons is provided. The method comprises a staining step and a visualizing step. The staining step comprises following steps: placing a neural tissue sample in an acrolein solution in the dark for fixation; placing the fixed neural tissue sample in a Golgi-Cox solution in the dark; replacing the Golgi-Cox solution; incubating the neural tissue sample placed in the replaced Golgi-Cox solution at a range of 36° C. to 38° C.; gradiently dehydrating the neural tissue sample; and embedding the dehydrated neural tissue sample with Petropoxy 154 resin. The visualizing step comprises: performing data acquisition and image reconstruction on the neural tissue sample using X-ray microscopy.Type: GrantFiled: May 22, 2020Date of Patent: August 1, 2023Inventor: Yeu-Kuang Hwu
-
Patent number: 11702636Abstract: An exemplary composition can be provided which includes an identified substance that induced cell reprogramming. Cells can also be provided having pluripotency having high safety when applied to regenerative medicine, using the composition, and a production method therefor. A cell reprogramming-inducing composition can include at least one 30S ribosome protein selected from the group consisting of 30S ribosome protein S2, 30S ribosome protein S8 and 30S ribosome protein S15 as a substance that reprograms cells derived from a mammalian animal is provided. Further, an exemplary production method for cells having pluripotency from somatic cells using the composition can be provided.Type: GrantFiled: November 15, 2016Date of Patent: July 18, 2023Assignee: National University Corporation Kumamoto UniversityInventors: Kunimasa Ohta, Naofumi Ito
-
Patent number: 11696929Abstract: The methods described herein are for conserving highly expanded cells that have functional properties such as potential for use in neotissue constructs. For example, highly expanded chondrocytes that can be used to construct neocartilage exhibiting functional properties similar to native articular cartilage. The methods and systems feature processes that form functional, human cartilage using cells that have been expanded to at least 1.5×105 times or P3 or greater. This enables a large quantity of engineered cartilage implants to be produced from few cells.Type: GrantFiled: September 20, 2018Date of Patent: July 11, 2023Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Kyriacos A. Athanasiou, Jerry C. Hu, Heenam Kwon
-
Patent number: 11696928Abstract: The invention relates to compounds as described herein and pharmaceutical compositions containing them. Also, the invention relates to methods for expanding stem cells and/or progenitor cells and methods for treating a hematopoietic disorder/malignancy, an autoimmune disease and/or an inherited immunodeficient disease.Type: GrantFiled: November 1, 2018Date of Patent: July 11, 2023Assignee: UNIVERSITE DE MONTREALInventors: Bruno Simoneau, Yves Chantigny, Jonathan Yeh, Guy Sauvageau, Anne Marinier
-
Patent number: 11696973Abstract: This invention discloses an implant for regeneration of tissue with lesions, comprising a mixture with different types of cells, particularly, mesenchymal stem cells (MSC), endothelial cells, and specific functional cells according to the nature and function of the tissue, included into the biocompatible polymeric matrix, where the cells may or may not be organized in a specific way. This innovation also discloses a method to manufacture the implant. The implant of the present invention is useful for replacement or regeneration of animal and human tissues.Type: GrantFiled: May 7, 2018Date of Patent: July 11, 2023Assignees: UNIVERSIDAD DEL VALLE, UNIVERSIDAD AUTONOMA DE OCCIDENTEInventors: Paola Andrea Neuta Arciniegas, Alvaro Jose Rojas Arciniegas, Jose Oscar Gutierrez Montes
-
Patent number: 11697795Abstract: The method of culturing cells disclosed herein includes printing cells onto a substrate that includes cell adhesive regions and cell repulsive regions. The cells are suspended in a printing medium to create a cell suspension, and a volume of the cell suspension is loaded into a printer. A cell adhesive region of the substrate is aligned beneath the printing channel of the printer, and droplets of the cell suspension are dispensed from the printing channel directly onto the cell adhesive region. Contact of the dispensed droplets with cell repulsive regions of the substrate is limited, either by targeting of the droplets to the cell adhesive regions, by repulsions generated by the cell repulsive areas, or both. The cells adhere to the cell adhesive regions to create a cell pattern, and are maintained thereafter in a physiologically suitable environment.Type: GrantFiled: August 7, 2019Date of Patent: July 11, 2023Assignees: University of Central Florida Research Foundation, Inc., Hesperos, Inc.Inventors: James J. Hickman, Sandra Rothemund, Megan Aubin, Frank Alexander
-
Patent number: 11684698Abstract: A sphere-like cell aggregate according to one embodiment of the present invention comprises: a core part containing neural retina; and a covering part continuously or discontinuously covering at least a portion of a surface of the core part.Type: GrantFiled: September 7, 2018Date of Patent: June 27, 2023Assignees: Riken, Sumitomo Pharma Co., Ltd.Inventors: Masayo Takahashi, Michiko Mandai, Suguru Yamasaki
-
Patent number: 11674903Abstract: A system and method for monitoring the health of dialysis patients with Raman spectroscopy measurements of one or more target analytes is described. The methods include irradiating one or more fluids of interest with light to produce one or more spectrum and detecting the spectrum with a detector. The fluids of interest are preferably those related to dialysis, including hemodialysis and peritoneal dialysis. In a preferred embodiment, the fluids are irradiated with monochromatic light, and one or more Raman spectra are detected as a result of the irradiation. The fluids may be irradiated within the dialysis tubing itself, or removed from the dialysis tubing and irradiated in a separate chamber. The Raman spectra of one or more target analytes of a dialysis patient may be followed over time or compared to one or more reference spectra, thereby providing information on the health of dialysis patients.Type: GrantFiled: April 23, 2015Date of Patent: June 13, 2023Assignee: Virginia Tech Intellectual Properties, Inc.Inventors: John L. Robertson, Ryan Senger, Pang Du
-
Patent number: 11666616Abstract: The present invention is concerned with a photosynthetic scaffold that delivers oxygen and its uses for tissue engineering and the treatment of ischemia.Type: GrantFiled: September 15, 2020Date of Patent: June 6, 2023Assignee: SYMBIOX, INC.Inventors: Jose-Tomas Egana-Erazo, Hans-Gunther Machens, Ursula Hopfner, Joerg Nickelsen
-
Patent number: 11659833Abstract: Provided are a vehicle body assembling method and a vehicle body assembling apparatus which allow a simple configuration in the vicinity of the connecting portion between an upper jig and a lower jig and allow an increase in the efficiency of assembling work (welding work). A vehicle body assembling apparatus is equipped with a jig for supporting vehicle body components in a preassembled position, the jig comprising an upper jig and a lower jig which are connected to each other in at least two places. Each of the connection places is provided with a connecting means for fixing a three-dimensional coordinate position while allowing uniaxial turning. The vehicle body assembling apparatus is also equipped with a conveying means for conveying the upper jig which supports the vehicle body components, and reduces the load applied to the lower jig from the upper jig when connecting the upper jig to the lower jig.Type: GrantFiled: August 22, 2017Date of Patent: May 30, 2023Assignee: BioVerde Inc.Inventors: Chikara Kubota, Takaaki Ando, Suong-Hyu Hyon, Woogi Hyon, Shuji Imamura, Satoru Gessei
-
Patent number: 11649431Abstract: Provided are cortical interneurons and other neuronal cells and in vitro methods for producing such cortical interneurons and other neuronal cells by the directed differentiation of stem cells and neuronal progenitor cells. The present disclosure relates to novel methods of in vitro differentiation of stem cells and neural progenitor cells to produce several type neuronal cells and their precursor cells, including cortical interneurons, hypothalamic neurons and pre-optic cholinergic neurons. The present disclose describes the derivation of these cells via inhibiting SMAD and Wnt signaling pathways and activating SHH signaling pathway. The present disclosure relates to the novel discovery that the timing and duration of SHH activation can be harnessed to direct controlled differentiation of neural progenitor cells into either cortical interneurons, hypothalamic neurons or pre-optic cholinergic neurons.Type: GrantFiled: October 23, 2015Date of Patent: May 16, 2023Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, CORNELL UNIVERSITYInventors: Lorenz Studer, Asif M. Maroof, Stewart Anderson
-
Patent number: 11639494Abstract: An embryo, gamete or stem cell culture medium comprising: a) acetyl-carnitine at a concentration of about 5 to about 50 ?M; and b) lipoic acid or a derivative thereof at a concentration of about 2.5 to about 40 ?M. The culture medium may optionally further comprises acetyl-cysteine at a concentration of about 5 to about 50 ?M.Type: GrantFiled: August 24, 2016Date of Patent: May 2, 2023Assignee: Vitrolife Sweden ABInventors: Thi Truong, David Gardner
-
Patent number: 11618883Abstract: The present invention provides a production method of a retinal pigment epithelial cell containing the following steps: (1) a first step for culturing a pluripotent stem cell in a medium containing at least one kind selected from the group consisting of an FGF receptor inhibitor and an MEK inhibitor for a period of not more than 30 days, and (2) a second step for culturing the cell obtained in the first step in a medium containing at least one kind selected from the group consisting of a Rho signal transduction pathway inhibitor and an apoptosis inhibitor to form a retinal pigment epithelial cell. The method can produce retinal pigment epithelial cells from pluripotent stem cells more efficiently and conveniently.Type: GrantFiled: March 8, 2018Date of Patent: April 4, 2023Assignees: SUMITOMO PHARMA CO., LTD., HEALIOS K.K.Inventor: Takao Kuroda
-
Patent number: 11612149Abstract: The present invention provides genetically modified non-human animals which are deficient in at least one or more types of CD3 genes selected from the group consisting of endogenous CD3?, CD3?, and CD3? in its genome and functionally express at least one or more types of human CD3 genes selected from the group consisting of human CD3?, CD3?, and CD3?. In the genetically modified non-human animals of the present invention, mature T cell differentiation and production can take place, and immunocompetent cells including T cells can exert their functions. The genetically modified non-human animals of the present invention enable efficient evaluation and screening in the development of therapeutic agents and therapeutic methods that use human CD3-mediated targeted drugs.Type: GrantFiled: July 8, 2016Date of Patent: March 28, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Koichi Jishage, Otoya Ueda, Naoko Wada, Takahiro Ishiguro, Yasuko Kinoshita